Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2019-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to study the impact of a strategy of a intensive glycemic control in patients undergoing cardiac surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

NCT00524472

Cardiac Surgery

COMPLETED NA

Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control

NCT00460499

Glycemic Control

COMPLETED PHASE1

Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery

NCT01361594

Diabetes

COMPLETED PHASE3

Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients

NCT01548963

Perioperative and Postoperative Hyperglycemia Tight Glycemia Control

COMPLETED NA

Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery

NCT01033916

Blood Glucose Coronary Artery Bypass Insulin +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients undergoing heart surgery at the Heart Institute (InCor) will be randomized and in accordance with a list of random numbers, generated by a computer program, are allocated in one of the treatment groups (conventional or intensive) when the blood glucose value recorded is greater than 200 mg/dl on two consecutive measures in an interval of 30 minutes.Conventional Group (GCon): patients randomized to the conventional group will receive insulin infusion in a dilution of 100 units of regular insulin in 100 ml of physiological solution (NaCl 0.9%) in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.

Group intensive (GInt): patients randomized to the intensive group will receive insulin infusion in a dilution of 100 units of regular insulin in 100 ml of physiological solution (NaCl 0.9%) in continuous infusion pump for maintenance of blood glucose between 90 mg/dl and 110 mg/dl.

The insulin dose adjustment will be based on measurements of arterial blood glucose undiluted, held at intervals of one to 4 hours with the use of a monitoring system of glucose and beta-blood ketone (Freestyle Precision Pro, Abbott). The dosage is adjusted according to an algorithm by a team of intensive care nurses, trained for this purpose and assisted by a study physician not involved in the clinical care of patients.

On admission, all patients will receive intravenous glucose solution continuously (200 to 300 g in 24 hours). As soon as possible, the patient will be nurtured according to the routine of Surgical ICU for nutrition in the postoperative period of cardiac surgery patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional Group

Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.

Group Type EXPERIMENTAL

Insulin

Intervention Type DRUG

All patients will receive insulin. However, the infusion flow will be different according to the group.

Moderate Group

Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.

Group Type EXPERIMENTAL

Insulin

Intervention Type DRUG

All patients will receive insulin. However, the infusion flow will be different according to the group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin

All patients will receive insulin. However, the infusion flow will be different according to the group.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glycemic Control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing heart surgery;
* Age greater than 18 years;
* Sign the informed consent form;
* Capillary blood glucose greater than 200mg/dL ICU admission

Exclusion Criteria

* Admitted for surgical repair of congenital heart defects;
* Dialytic Chronic renal failure;
* Participation in other research protocol;
* Diagnosis of HIV/AIDS;
* Pregnant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No